Parkinson's disease (PD) is a neurodegenerative condition with several major hallmarks, including loss of neurons, reduction in striatal dopaminergic function, and formation of α-synuclein-rich Lewy bodies. Mutations in , encoding for α-synuclein, are a known cause of familial PD, and the G51D mutation causes a particularly aggressive form of the condition. CRISPR/Cas9 technology was used to introduce the G51D mutation into the endogenous rat gene. and rats were born in Mendelian ratios and did not exhibit any severe behavourial defects. -3,4-dihydroxy-6-F-fluorophenylalanine (F-DOPA) positron emission tomography (PET) imaging was used to investigate this novel rat model. Wild-type (WT), and rats were characterized over the course of ageing (5, 11, and 16 months old) using F-DOPA PET imaging and kinetic modelling. We measured the influx rate constant () and effective distribution volume ratio () of F-DOPA in the striatum relative to the cerebellum in WT, and rats. A significant reduction in was observed in rats at 16 months of age indicative of increased dopamine turnover. Furthermore, we observed a significant asymmetry in between the left and right striatum in aged rats. The increased and asymmetric dopamine turnover observed in the striatum of aged rats reflects one aspect of prodromal PD, and suggests the presence of compensatory mechanisms. rats represent a novel genetic model of PD, and kinetic modelling of F-DOPA PET data has identified a highly relevant early disease phenotype.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244711 | PMC |
http://dx.doi.org/10.3389/fnins.2023.1095761 | DOI Listing |
J Endocrinol Invest
December 2024
Nuclear Medicine and Molecular Imaging, ICANS, Strasbourg University Hospitals, Strasbourg University, Strasbourg, France.
Purpose: To investigate the influence of germline succinate dehydrogenase (SDHx) pathogenic variants on 6-[F]-fluoro-3,4-dihydroxyphenylalanine (F-DOPA) Positron Emission Tomography (PET) radiomic signature of head and neck paragangliomas (HNPGLs).
Methods: Forty-seven patients (20 SDH pathogenic variants carriers) harboring 55 HNPGLs were retrospectively included. HNPGLs were delineated using Nestle adaptive threshold.
Lancet Oncol
December 2024
Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Background: Older patients (aged ≥65 years) with glioblastoma have a worse prognosis than younger patients and a median overall survival of 6-9 months. 3,4-Dihydroxy-6-[F]fluoro-L-phenylalanine (F-DOPA) PET sensitively and specifically identifies metabolically active glioblastoma for preferential targeting. Proton beam therapy potentially improves quality of life (QOL) by sparing more healthy brain tissue than photon radiotherapy.
View Article and Find Full Text PDFJ Clin Med
October 2024
Department of Informatics, Bioengineering, Robotics and System Engineering (DIBRIS), University of Genoa, 16145 Genoa, Italy.
Eur J Neurol
December 2024
Department of Nuclear Medicine and PET, Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Background And Purpose: Most patients with isolated rapid eye movement sleep behaviour disorder (iRBD) progress to a parkinsonian alpha-synucleinopathy. However, time to phenoconversion shows great variation. The aim of this study was to investigate whether cholinergic and dopaminergic dysfunction in iRBD patients was associated with impending phenoconversion.
View Article and Find Full Text PDFQ J Nucl Med Mol Imaging
September 2024
Nuclear Medicine Unit, Department of Medical Sciences, AOU Città della Salute e della Scienza, Turin, Italy -
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!